Invion Conference Presentation
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
INVION CONFERENCE PRESENTATION
MELBOURNE (AUSTRALIA) 18 October 2022: Invion Limited (ASX: IVX) (“Invion” or the
“Company”) will be presenting at the 11th Annual Australian Microcap Investment Conference
today at 11.45 am.
Invion’s Executive Chairman and Chief Executive Officer, Thian Chew, will be using the
attached presentation at the conference, which is held at the Sofitel Melbourne.
This announcement was approved for release by Thian Chew, Chairman of the Board.
____________________________________________
Investor and Media enquiries:
Thian Chew (Chairman & CEO)
T: +61 3 9692 7222
E: investor@inviongroup.com
Brendon Lau (Investor & Media Relations)
M: +61 409 341 613
E: brendon.lau@inviongroup.com
About Invion
Invion is a life-science company that is leading the global research and development of the
PhotosoftTM technology for the treatment of a range of cancers, atherosclerosis and infectious
diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive
distribution rights to Asia Pacific excluding China (other than Hong Kong, which is included in
the Territory), Macau, Taiwan, Japan and South Korea to the PhotosoftTM technology for all
cancer indications. It also holds the exclusive rights to the technology in Asia Pacific (excluding
Greater China) for atherosclerosis and infectious diseases. Research and clinical cancer trials
are funded by the technology licensor, RMW Cho Group Limited, via an R&D services
agreement with the Company. Invion is listed on the ASX (ASX: IVX). For more information, visit
www.inviongroup.com.
About Photodynamic Therapy (PDT)
Invion is developing PhotosoftTM technology as a novel next generation Photodynamic
Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and
promote an anti-cancer immune response. Less invasive than surgery and with minimal side
effects, PDT offers an alternative treatment option aimed at achieving complete tumour
regression and long-lasting remission.
Invion Limited ABN 76 094 730 417
100 Albert Road, South Melbourne, VIC 3205
P: +61 3 9692 7222 W: www.inviongroup.com
INVESTOR
PRESENTATION
October 2022
DISCLAIMER
The information in this presentation does not constitute personal investment
advice. The presentation is not intended to be comprehensive or provide all
information required by investors to make an informed decision on any
investment in Invion Limited (Company). In preparing this presentation, the
Company did not take into account the investment objectives, financial
situation and particular needs of any particular investor. Further advice should
be obtained from a professional investment adviser before taking any action on
any information dealt with in the presentation. Those acting upon any
information without advice do so entirely at their own risk. Whilst this presentation
is based on information from sources which are considered reliable, no
representation or warranty, express or implied, is made or given by or on behalf
of the Company, any of its directors, or any other person about the accuracy,
completeness or fairness of the information or opinions contained in this
presentation. No responsibility or liability is accepted by any of them for that
information or those opinions or for any errors, omissions, misstatements
(negligent or otherwise) or for any communication written or otherwise,
contained or referred to in this presentation. Accordingly, neither the Company
nor any of its directors, officers, employees, advisers, associated persons or
subsidiaries are liable for any direct, indirect or consequential loss or damage
suffered by any person as a result of relying upon any statement in this
presentation or any document supplied with this presentation, or by any future
communications in connection with those documents and all of those losses
and damages are expressly disclaimed. Any opinions expressed reflect the
Company’s position at the date of this presentation and are subject to change.
2
Next Generation Photodynamic Therapy | October 2022
COMPANY OVERVIEW
DEVELOPING THE NEXT-GEN PHOTODYNAMIC THERAPY (PDT)
Major disease areas: Cancer + atherosclerosis and infectious diseases (AID)
Advancing Photosoft™ technology – novel PDT photosensitiser INV043
Collaboration with world-class expertise (Hudson Institute, Peter Mac)
Regression of established tumours across multiple cancer types
Immune response, protective immunity
Improves efficacy of immune checkpoint inhibitor (ICI) treatments when used in
combination therapies
Strong therapeutic profile: Non-toxic at 100x therapeutic dose
Multiple
Cancers,
Future Potential
Clinical stage cancer program
Multiple cancer indications in Asia Pacific Territories2
Expanded Disease Areas: Atherosclerosis and Infectious Diseases (AID)
Promising in vitro results: Multiple viruses and strains (Zika, SARS-CoV-2 Delta and Omicron)
Sources of Value
Creation
Clinical trials across multiple cancer indications in 2022-2023 and beyond
Core clinical development funded by RMWC, inventor/ owner of Photosoft™
Expansion of Territories in AID1 and cancer2
Potential to partner
Meeting Clinical
Needs
Demonstrated
Cancer Efficacy,
Protective
Immunity
1 Includes Asia and Oceania (other than Australia and New Zealand, which are covered under a pre-existing distribution and licence agreement with RMW), and excludes
Middle East, Russia and the specified territories of China, Hong Kong, Macau and Taiwan.
2 Includes all Asia Pacific countries excluding China (other than Hong Kong, which is included in the Territory), Macau, Taiwan, Japan and South Korea. Invion’s rights with respect to development
and distribution of Photosoft™ technology in Australia and New Zealand will continue to be covered under the pre-existing agreements with RMW. Closing of transaction subject to shareholder
approval.
3
THE PHOTOSOFTTM ADVANTAGE
A NOVEL CANCER TREATMENT
NGPDT (Next-Gen PDT) is a ground-breaking
technology that overcomes many of the
shortcomings of early PDT technologies and
aims to transform the treatment of a wide
range of cancers
NGPDT is a minimally invasive modality for
treating cancer that specifically identifies and
destroys cancer cells whilst leaving the rest of
the body’s normal cells unharmed
Photodynamic Therapy (PDT) consists of three elements:
1
Combines photosensitiser
compound with lightinduced activation
Generates reactive
oxygen species (“ROS”)
causing damage to only
targeted cells
2
3
Direct cell death along
with activation of immune
response
Light
Necrosis
Photosensitiser
accumulation in
tumour tissue
01
4
Cellular
localisation
Generation of
reactive O2
02
03
Next Generation Photodynamic Therapy | October 2022
Cellular
damage
04
Cell
death via
05
Apoptosis
Autophagy
LEAD CANCER DRUG CANDIDATE INV043
PATHWAY TO A US$271B MARKET OPPORTUNITY1
Proof-of-Concept studies of lead candidate INV043 has been shown to:
Selectively absorbed by cancer cells and not healthy tissue
Invion is leading the
global research and
development of the NextGeneration
Photodynamic Therapy
(NGPDT) called
PhotosoftTM for the
treatment of a range of
cancers, atherosclerosis
and infectious diseases
Effective in regressing multiple types of cancer in vivo
Stimulate the body’s natural immune response
Work additively with blockbuster ICI2 drugs
Be non-toxic, safe and have limited side effects
Support the translation into successful clinical trials3
1 Oncology market exceeded US$270.5 billon in 2021 and is forecast to grow at 10.2% CAGR between 2022 and 2028, according to GMI
2 Immune Checkpoint Inhibitor (ICI) therapies are part of the Immunotherapy market
3 Scheduled for 2H CY2022 or 1H CY2023
5
Next Generation Photodynamic Therapy | October 2022
KEY PARTNERSHIPS
WORLD-LEADING INSTITUTIONS
•
Global bioscience medical research institute
•
•
Over 400 scientists focused on ground-breaking
discoveries addressing complex problems in
human diseases including cancer
World-class institute that combines its premier
cancer research capability with its ability to
translate that directly into the clinic
•
Currently conducting about 500 clinical trials in
cancer
•
Photosoft™ discovery and development
•
Proof of Concept studies focused on safety
and efficacy1
•
Pre-clinical studies initially focus on high-risk
ano-genital cancers
•
Translational work into clinical trial preparations
•
Successful studies will pave the way for human
clinical trials
1 https://inviongroup.com/videos-reports/
6
Next Generation Photodynamic Therapy | October 2022
Cancer Findings
Proof-of-Concept Studies on INV043
IMPROVED API: INV043
KEY CHARACTERISTICS*
Active against multiple cancers
Highly potent and selective
• INV043 successfully regressed
established T-cell lymphoma,
triple negative breast and
pancreatic cancers in vivo
(n=4-8/group).
• ~600x greater photoxicity
than Talaporfin sodium (a
widely used photosensitiser).
• Formulations enable multiple
routes of administration.
• No “dark” toxicity” until 20 to
300 times the therapeutic
dose.
• Treatment activates an
immune response.
• No observed off target
toxicity.
Strong therapeutic profile
Theragnostic potential
• No toxicity identified up to
100x the therapeutic dose
• Selectively retained into
tumours in vivo:
Two distinct light activations
wavelengths
o Within hours accumulates in
tumour mass
o Within a day INV043 is not
detectible in healthy tissue
o Remains concentrated
within tumour mass for >3
days
INV034 activity against multiple cancer cell types
INV043 fluorescing in a tumour under light
• Diagnostic: Fluorescence
providing highly visible
definition of tumour mass
and margins.
• Therapeutic: Activation of
INV043 causes rapid
cancer cell death and
tumour regression.
*Studies carried out by Hudson Institute
8
Next Generation Photodynamic Therapy | October 2022
PROOF OF CONCEPT: PRIMARY TUMOUR PILOT STUDY
REGRESSION AND PROTECTIVE IMMUNITY
Treatment with established tumours (INV043 with light)
•
INV043 was injected intratumorally (0.1mg/kg)
•
16 hours later, illuminated with red light
•
No anaesthesia required, no adverse effects observed
Immune competent
mice with TNBC
(n=3/group)
Day 0
Day 6
Day 15
Orthotopic
implantation of
4T1 TNBC cells
TREATMENT
GROUP
CONTROL
GROUP
9
Day 35
Day 17 Day 19 Day 21
Orthotopic
reimplantation
of 4T1 TNBC cells
No adverse
effects
observed
1. No treatment
2. INV043 alone (no light)
3. Light alone (no INV043)
Tumour
regression
observed
Tumour mass
undetectable
No tumour
detectable
• Enlarged rapidly and reached endpoint (Tumour size >100mm2)
• Obvious metastatic involvement of lungs and abdominal fat
pad at autopsy
Next Generation Photodynamic Therapy | October 2022
The research activities involving the use of animals were carried out in accordance with relevant
guidelines and regulations as well as with appropriate Animal Ethics Committee approval.
PROOF OF CONCEPT: PRIMARY TUMOUR PILOT STUDY
REGRESSION AND PROTECTIVE IMMUNITY
•
Triple Negative Breast Cancer (TNBC) is a hard-to-treat cancer resistant to most chemotherapies
•
Proof of Concept (PoC) pilot showed complete regression of TNBC in vivo following INV043 treatment
•
Tumour mass undetectable two weeks after initial treatment and no scarring evident
•
No recurrence of disease, re-challenge with TNBC implant could not re-establish new tumours, suggesting
development of protective immunity
•
Additional PoC tests being carried out by Hudson Institute
Endpoint
Tumour volume
Control
Pretreatment
Treated
Mice with established 4T1
breast tumours treated with
INV043 PDT at days 6 and 13
post-implant. Tumour size
monitored until endpoint
(>100mm2). Treatment
regressed established tumours
to an undetectable level
within 14 days of treatment.
No tumour regrowth observed.
n=3/group; mean +/- SD
https://inviongroup.com/videos-reports/
10
Figure 4. PDT using INV043
results in complete
regression of established
tumours.
Next Generation Photodynamic Therapy | October 2022
The research activities involving the use of animals were carried out in accordance with relevant
guidelines and regulations as well as with appropriate Animal Ethics Committee approval.
ANAL CANCER SCC
PROMISING RESULTS AGAINST NEW CANCER CLASS*
Cytotoxicity data of human anal SCC cells lines
In vitro study showed INV043’s effectiveness against six
squamous cell carcinoma (SCC) cell lines that
represent the full range of anal cancers
Most anal cancers are SCCs and are difficult to treat
with the global market estimated to be worth US$1.3bn
by 2028 (6.3% CAGR)1
Findings were consistent with the results of work done
at the Hudson Institute on other cancer types
Preclinical testing using topical delivery of INV043
started as a prelude to moving to clinical human
testing of anal SCC
1Source:https://www.coherentmarketinsights.com/
market-insight/anal-cancer-market-4701
11
Next Generation Photodynamic Therapy | October 2022
*Studies carried out by Peter Mac
PROOF OF CONCEPT: IMMUNE CHECKPOINT INHIBITORS (ICI)
COMBINATION THERAPY FOR A US$140B MARKET1 (BY 2030)
•
Immune checkpoint inhibitors are widely used for the treatment of lung cancer and melanoma. However, ICI
treatments are typically only effective on a small proportion of patients
•
Proof of Concept (PoC) pilot by Hudson Institute showed both INV043 (under restricted administration) and
anti-PD-1 therapies achieved a very similar level of tumour growth restriction following therapy, with tumour
growth reduced by ~40% compared to controls
•
A combination of INV043 with anti PD-1 provided substantially enhanced restriction (~65%) of tumour growth,
with clear tumour regression despite the sub-optimal INV043 treatment protocol used
Figure 5. INV043-PDT combines with immune checkpoint
inhibition to regress tumour mass.
Mice with established 4T1 breast tumours were treated using a
restricted INV043 PDT protocol and / or anti PD-1 antibody over
a period of 14 days. Tumour size was monitored until endpoint
(tumour size >100mm2).
Combi therapy:
>60% increase in
effectiveness vs. ICI
alone
Monotherapies restricted tumour growth compared to
untreated controls; combination therapy regressed and
stabilized tumours and achieved a ~65% reduction in tumour
size at endpoint. INV043 control, no light activation; IgG2a
control, isotype antibody control; combination, PDT+ anti PD-1.
Additional control groups have been omitted for clarity. mean
+/- SD, n=4/group.
The research activities involving the use of animals were carried out in accordance with
relevant guidelines and regulations as well as with appropriate Animal Ethics Committee
approval.
12
Next Generation Photodynamic Therapy | October 2022
1 https://www.alliedmarketresearch.com/immune-check-point-
inhibitors-market
The research activities involving the use of animals were carried out in accordance with relevant
guidelines and regulations as well as with appropriate Animal Ethics Committee approval.
Infectious Diseases
Findings
In Vitro Studies on Infectious Diseases
EFFECTIVE AGAINST SARS-CoV-2 IN VITRO
ANTIVIRAL ACTIVITY AGAINST DELTA AND OMICRON VARIANTS
Selected PhotosoftTM Compounds vs. Remdesivir - Delta
Nine out of ten PhotosoftTM compounds tested
displayed antiviral activity against both Delta
and Omicron variants of SARS-CoV-2
% Inhibition
100
Multiple PhotosoftTM compounds show
effectiveness against SAR-CoV-2 at far lower
concentrations than Remdesivir
80
60
40
20
0
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Concentration µM
Antiviral activity occurred once PhotosoftTM
compounds were activated with red light
% Inhibition - Compound 7
% Inhibition - Remdesivir
% Inhibition - Compound 9
% Inhibition - Compound 10
Selected PhotosoftTM Compounds vs. Remdesivir - Omicron
PhotosoftTM compounds tested demonstrated
either no or low cytotoxicity
The global coronavirus treatment market is
forecast to reach US$49bn by 2027 (17.5%
CAGR)*
*https://www.coherentmarketinsights.com/market-insight/coronavirus-treatment-drugs-market-4312
14
Next Generation Photodynamic Therapy | October 2022
% Inhibition
100
80
60
40
20
0
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
Concentration µM
% Inhibition - Compound 7
% Inhibition - Remdesivir
% Inhibition - Compound 9
% Inhibition - Compound 10
0.9
1
EFFECTIVE AGAINST ZIKA IN VITRO
ANTIVIRAL ACTIVITY AGAINST ZIKA
Example of a PhotosoftTM compound vs Monensin
Percentage (%) inhibition
100
90
80
70
60
50
40
30
20
10
0
-0.1
% Inhibition - PhotosoftTM compound
% Cytotoxicity - PhotosoftTM compound
% Inhibition - Monensin
% Cytotoxicity - Monensin
0.1
0.3
0.5
0.7
0.9
1.1
1.3
1.5
Concentraton (uM)
PhotosoftTM compounds demonstrated ≥99%
inhibition against Zika virus in cell-based
assays following application of light
Several PhotosoftTM compounds had over 100
times the activity of Monensin3 (selected
control) in vitro
Zika virus is found in 86 countries and has
been linked to birth defects and other
neurological complications
The Zika virus market estimated to be worth
~US$17 billion in 20221 with no vaccines or
treatments for the disease currently available2
1https://www.marketdataforecast.com/market-reports/zika-virus-vaccines-market
2https://www.who.int/news-room/fact-sheets/detail/zika-virus
3 Monensin is an antibiotic which is known to have activity against Zika in in vitro laboratory tests and was used as a control (benchmark) in this study, but due to its in
vivo toxicity cannot be used in humans.
15
Next Generation Photodynamic Therapy | October 2022
THE WAY FORWARD
MULTIPLE CATALYSTS AND MILESTONES
Australia
Proof of Concept (PoC) Building on in vivo work further
demonstrating both safety and efficacy profiles
•
Pre-clinical Preparations: Building foundations for clinical
trials in multiple indications and internationally
•
Clinical Trials: With strong in vitro and in vivo results
demonstrating both safety and efficacy profiles, and across
multiple cancer types, the next steps will be to conduct
clinical trials in multiple indications, including
•
•
Skin Cancer (superficial basal cell carcinoma)
•
Anogenital Cancer
•
Other solid tumour cancers TBC1
GMP manufacturing and scale up: Building capacity to
scale up for global late-stage trials and commercialisation
AID
Atherosclerosis and
Infectious Diseases
(AID)
Early stage broad
based discovery
Identification of
target indications
1 RMW Cho Group (“RMW”)
Global
Cancer
•
Expand
Internationally:
Leveraging
Australian clinical
trial data into later
stage programs in
other major
markets
Proof of Concept
on targeted
indications
as licensor of PhotosoftTM technology, is pursuing independent research in parallel with Invion’s R&D efforts
including a prostate cancer trial. The research is complementary/supplemental to Invion’s development program. To the extent that
Invion becomes aware of material information relating to RMW’s studies, Invion will release the information to the ASX in compliance with
its disclosure obligations (noting however that Invion is not involved in RMW’s studies and does not have direct access to information)
16
Next Generation Photodynamic Therapy | October 2022
MANAGEMENT TEAM
THE RIGHT EXPERTISE FOR SUCCESS
THIAN CHEW
EXECUTIVE CHAIRMAN & CEO
MELANIE LEYDIN
CFO
• Managing Partner, Polar Ventures
• Executive Director, Goldman Sachs
• Director, KPMG Consulting, Senior Manager KPMG
• Adj. Prof. HKUST, MBA/MA Wharton School
• 25+ years in accounting profession
• Partner, Vistra
• CFO and Co. Secretary multiple biotech companies
• Fellow Gov. Institute of Australia, Chartered Acc’t
DR ANDREW STEPHENS
HUDSON INSTITUTE, R&D
NICOLETTA MUNER
REGULATORY AND CLINICAL DEVELOPMENT
• 15+ years in novel treatment R&D
• 20+ years non-clinical and clinical drug development, quality,
manufacturing, incl. EMA and US FDA approval
• Founder, Ovarian Cancer Biomarker Group, Hudson Institute
17
• Postdoc. positions, the Uni. of Sydney and Prince Henry’s Institute,
PhD Biochemistry Monash Uni
• Founder Canary Regulatory Affairs
• Published extensively, holds several patents
• Pre-clinical and regulatory affairs, Pfizer
DR SEBASTIAN MARCUCCIO
CHEMISTRY
LOUISE WHITE
MANUFACTURING AND QUALITY
• 15+ years in Pharmaceutical and organic chemistry
developmental research
• 35+ years in the pharmaceutical industry, 13 years in vaccine
manufacturing, CSL, Partner SeerPharma
• 16+ years commercial experience in molecular based companies
(Managing Director / Founder)
• Senior roles in virology R&D, bacterial vaccines production,
quality control and production planning
• Adj. Prof. La Trobe University, PhD Organic Chemistry ANU
• Registered auditor for APVMA
ALEXANDER BENNETT
TECHNICAL ADVISOR, LIGHT
KIM STEEL
CLINICAL TRIAL MANAGEMENT
• 35+ years in R&D, manufacturing and commercialisation of
scientific instrumentation incl. ISO certifications
• 15+ years managing global and clinical drug and
device studies from Phase 1-IV across 14 countries
• GM Forensic Light Sources, Rofin Australia.
• Director, Sapro Consulting
• Led Medical Light Source trial for PDT in skin cancers Peter
MacCallum Cancer Centre
• Project Director, Novotech
Next Generation Photodynamic Therapy | October 2022
• Global Regulatory Affairs, Clinuvel Pharmaceuticals
• Project Manager, Pacific Clinical Research Group
SUMMARY
18
Cancer - Promising Results:
Total tumour regression,
immune response, potential ICI
combination therapies
Infectious Diseases – Early Findings:
In vitro effectiveness against multiple
viruses including SARS-CoV-2 (Delta
and Omicron) as well as Zika
Cancer - Clinical Trials: Human trials
across several cancer types expected
to commence 2022-2023
Well Funded: Cancer program fully
funded & AID partially funded by
RMWC
Multiple Growth Options: Large
addressable markets, multiple
indications, partnership opportunities
Experienced Management, WorldLeading Partnerships:
Balance of expertise in life sciences
and commercialisation combined with
world-renowned partnerships
Next Generation Photodynamic Therapy | October 2022
YTD Share Price*
MARKET OVERVIEW
$0.012
(as of 03 Oct 2022)
Market Cap
A$77m
Focus
Issued Shares
Cash
(30 Sep 2022)
Revenue
(Year ended 30 June 2022)
Symbol/ Exchange
19
Clinical-stage life sciences
company developing the
PhotosoftTM technology as
a treatment for a range of
diseases including cancers
6,420,092,081
AUD $7.8M
$3.292M
ASX: IVX
TOP 10 SHAREHOLDERS
%IC
Polar Ventures Limited
8.49
BNP Paribas Nominees Pty Ltd
7.99
RMW Cho Health Technology Ltd
5.01
RMWC Pty Ltd
4.90
Mr Honsue Cho
4.43
NGPDT Greater China Ltd
4.25
Mei Jun Lin
4.24
ACSLNC Pty Ltd
3.79
Yong Chen
3.12
Citicorp Nominees Pty Ltd
2.32
*As of 03 Oct 2022
Share your feedback
Discover